CJC-1295 No DAC 5mg lyophilised research peptide vial

CJC-1295 (No DAC) — 5 mg

£18.99

  • ≥99% Purity (HPLC)
  • Batch-tested & CoA available
  • For research use only

CJC-1295 no DAC (also written as CJC-1295 (No DAC) or Mod GRF(1–29)) is a growth hormone–releasing hormone (GHRH) analogue used for in-vitro studies of GHRH receptor signalling, cAMP/PKA pathways, and GH-axis models under controlled, non-clinical conditions.

This listing refers to the non-DAC (short, Mod GRF(1–29)) variant, which researchers select to probe ligand–receptor engagement, second-messenger dynamics, and structure–activity relationships in cell systems.
For laboratory research only. Not for human use.

FOR LABORATORY RESEARCH USE ONLY

This product is supplied exclusively for scientific laboratory research. It is not intended for human or veterinary use or administration, therapeutic use, diagnostic use or clinical application.

Avanti Peptides does not provide advice regarding human administration, dosage, injection, reconstitution for administration, treatment protocols or therapeutic use.

Regulatory status

This product is sold as a laboratory research material and is not offered or promoted as a medicinal product. No therapeutic or medical claims are made for this product.

SKU: CJC-5MG Category: Tags: ,

Description

≥99% Purity (HPLC)
Batch-tested & CoA available
Lyophilised — stable at room temp
For research use only

Product overview

CJC-1295 (No DAC) — also known as Modified GRF(1–29) or Mod GRF(1–29) — is a synthetic, tetrasubstituted analogue of growth hormone–releasing hormone (GHRH). Unlike the DAC version, CJC-1295 No DAC lacks the Drug Affinity Complex that extends half-life in vivo, making it well-suited for in-vitro studies of GHRH receptor (GHRHR) signalling where a defined, short-duration stimulus is required. Avanti Peptides supplies it as a lyophilised solid for stable, consistent research use.

Why researchers choose Avanti CJC-1295 (No DAC): Manufactured via validated SPPS and released only after identity, purity (≥99% HPLC), and appearance checks — providing lot-to-lot consistency for GHRHR pharmacology studies.

Key features

  • GHRH analogue (non-DAC) — ideal for in-vitro GHRHR signalling and GH-axis biology studies
  • Tetrasubstituted Mod GRF(1–29) — enhanced protease resistance versus native GHRH(1–29)
  • Lyophilised solid — stable, easy to store, and straightforward to reconstitute
  • Unit size: 5 mg per vial
  • Every batch released only after stringent identity, purity, and appearance QC
  • Certificate of Analysis (CoA) and batch documentation available on request

Technical specifications

Product name CJC-1295 (No DAC) / Modified GRF(1–29)
Synonyms CJC-1295 no DAC; Mod GRF(1–29); tetrasubstituted GRF(1–29)
Class Growth hormone–releasing hormone analogue (non-DAC)
Purity ≥99% (HPLC)
Physical form Lyophilised powder
Appearance White to off-white solid
Unit size 5 mg / vial
Note Exact properties may vary by counter-ion/hydration state

Reconstitution & storage

  1. Before reconstitution: Store lyophilised vials at 2–8 °C, protected from light and moisture.
  2. Equilibrate: Allow vial and diluent to reach room temperature before opening.
  3. Reconstitute: Add Bacteriostatic Water (10 ml recommended). Swirl gently — do not vortex.
  4. After reconstitution: Store at 2–8 °C. Prepare aliquots to minimise freeze–thaw cycles.
  5. Compatibility: Use only within protocols that comply with your institution’s SOPs and local regulations.

Looking for complementary materials? See Bacteriostatic Water 10 ml and GH-axis research companions such as Ipamorelin 5 mg and GHRP-6 10 mg.

About CJC-1295 (No DAC) in research

Researchers use CJC-1295 (No DAC) to investigate GHRH receptor activation, downstream GH-axis signalling cascades, and the effect of GHRH analogues on pituitary cell models in vitro. Its tetrasubstituted sequence confers greater stability than native GHRH(1–29) while the absence of a DAC moiety allows study of short-duration receptor stimulation kinetics.

Synthesis & quality assurance

Avanti Peptides manufactures CJC-1295 (No DAC) via controlled, validated solid-phase peptide synthesis (SPPS) to deliver high purity and lot-to-lot consistency. Each batch undergoes identity verification, HPLC purity analysis (≥99%), and appearance inspection before release. Certificate of Analysis (CoA) documentation is available upon request.

FAQs

What is CJC-1295 (No DAC)?
CJC-1295 (No DAC), also called Modified GRF(1–29), is a tetrasubstituted GHRH analogue used for in-vitro studies of GHRH receptor pharmacology and GH-axis signalling. Unlike the DAC form, it does not contain a drug-affinity complex, making it suitable for short-duration stimulation assays.
How should I store the peptide?
Store lyophilised vials at 2–8 °C, away from light and moisture. After reconstitution, keep at 2–8 °C and use aliquots to minimise freeze–thaw cycles.
What diluent should I use for reconstitution?
Most laboratories use Bacteriostatic Water (10 ml). Always follow your lab’s standard operating procedures (SOPs) for the specific assay.
Do you provide batch documentation / Certificate of Analysis?
Yes. Batch documentation including test results (CoA) is available on request. If it is not attached to your order confirmation, contact our support team and we will add it immediately.
Is this product intended for human use?
No. This material is strictly for laboratory research only and is not intended for human consumption, clinical application, or veterinary use.

Legal & safety notice

For research use only. Avanti Peptides supplies this material strictly for laboratory research. This product is not a medication, food supplement, or cosmetic and is not intended for human or veterinary use. By purchasing, you confirm that you are a qualified researcher and will handle the material in accordance with your institution’s policies and all applicable laws and regulations.

External resources for researchers

Related products